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Abstract
Background Neurofibromatosis type I (NF1) predisposes
patients to various neoplasias, including gastrointestinal
stromal tumors (GISTs). Little is known about the risk of
developing GISTs for NF1 patients or the clinicopathologic
features and prognosis of NF1-GIST.
Methods We conducted a multi-detector computed
tomography screen for adult NF1 patients between 2003
and 2012. Clinicopathologic data of sporadic GISTs from
patients who underwent surgery between 2001 and 2010
were retrospectively collected from 32 hospitals in Japan.
Results CT screening identified 6 GIST patients from the
95 NF1 patients screened, suggesting that the prevalence
rate of GISTs was approximately 6.3/100 in NF1 patients.
All 6 NF1 patients exhibited hyperplasia of the interstitial
cells of Cajal in the adjoining small intestine. NF1-GISTs
may account for 1.1–1.3 % of primary sporadic GISTs and
present as multiple tumors in the small intestine, with low
mitotic activity and no KIT or PDGFRA mutations. The risk
of recurrence and mortality is very similar between NF1 and
non-NF1 patients after surgical resection of GISTs.
Conclusions NF1 patients may be predisposed to devel-
oping small intestinal GISTs, which may appear as multi-
ple GISTs without KIT and PDGFRA mutations. The
prognosis of patients with NF1-GISTs is similar to patients
with conventional GISTs.
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Abbreviations
GIST Gastrointestinal stromal tumor
IHC Immunohistochemistry
ICC Interstitial cells of Cajal
MDCT Multi-detector computed tomography
MPNST Malignant peripheral nerve-sheath tumors
NF1 Neurofibromatosis type I
NF1-GIST GIST associated with NF1
OS Overall survival
PD Progressive disease
RFS Recurrence-free survival
SDH Succinate dehydrogenase
Introduction
Gastrointestinal stromal tumors (GISTs) predominantly
occur in the stomach (60–70 %) and small intestine
(20–30 %), and multiple tumors are rarely observed [1, 2].
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GIST proliferation may be caused by gain-of-function
mutations in either the KIT (80–85 %) or PDGFRA (10 %)
genes [2]. Five to ten percent of GISTs lack mutations in
these genes (wild-type GISTs). Such wild-type GISTs are
now known to be heterogeneous and may actually possess
mutations in the SDH complex genes, NF1, BRAF, NRAS,
or HRAS. Imatinib mesylate, a selective tyrosine kinase
inhibitor of KIT, PDGFR-a, and Abl, exhibits exceptional
activity in advanced GIST patients. The benefits of ima-
tinib have largely been observed in KIT- and PDGFRA-
mutant GISTs; however, its activities are less well docu-
mented in wild-type GISTs [2].
Neurofibromatosis type I (NF1), also known as von
Recklinghausen disease, is an autosomal dominant inher-
ited syndrome affecting 1/3000–4000 individuals [3]. NF1
is distinguished by a variety of characteristic features and is
clinically diagnosed using the National Institutes of Health
diagnostic criteria [4]. NF1 is believed to be caused by
functionally biallelic losses of the tumor suppressor gene
NF1, resulting in the functional loss of neurofibromin. NF1
patients are predisposed to both benign and malignant
tumors, including neurofibroma, optic-pathway glioma,
malignant peripheral nerve-sheath tumors (MPNSTs),
neuroblastoma, GIST, pheochromocytoma, and breast
cancer [3].
A number of case reports and small case series have
indicated a strong association between NF1 and GIST [3,
5].The clinicopathologic features of GISTs associated with
NF1 are different from those of sporadic GISTs. Most NF1
patients, for instance, exhibit multiple GISTs in the small
intestine, and NF1-GISTs rarely exhibit mutations in the
KIT and PDGFRA genes [3, 7]. However, the existing
studies of NF1-GISTs have been primarily conducted in
Caucasian populations and are mostly case series with
small numbers of patients or case reports. Some conflicting
results were observed from these reports, [9, 10] and the
incidence of GISTs in Japanese NF1 patients and the
clinicopathologic features of NF1-GISTs in a Japanese
population have not yet been established. Furthermore, to
date, no report has demonstrated the outcomes of surgery
and prognosis for NF1-GIST patients.
Although NF1 may be associated with an increased risk
for GIST, little is known about the lifetime risk of devel-
oping a GIST in NF1 patients. Moreover, the frequency of
NF1-GIST development among sporadic GISTs and the
clinicopathologic characteristics and prognosis of NF1-
GIST remain unknown. In this study, we, therefore, eval-
uated NF1 patients by CT screening, and retrospectively
analyzed the clinical and pathological characteristics of any
identified NF1-GISTs. We also assessed NF1-GIST patient
prognosis.
Patients and methods
NF1 patient screening with multi-detector CT
(MDCT)
Because of the suspected high incidence of intestinal
GISTs in adult NF1 patients, we planned and conducted
multi-detector computed tomography (MDCT) screening.
We recommended MDCT to adult NF1 patients over
30 years old who visited the Department of Dermatology
at the Osaka University Hospital as well as to NF1
patients with signs and symptoms of the disease. The
MDCT screening was offered to 158 NF1 patients
between April 2003 and September 2012. Of these 158
NF1 patients, informed consent was obtained from 95,
and they received MDCT with or without contrast media.
We recommended the use of contrast media; however,
when patients had a suspected allergy to the media or
refused its use, a plain CT was performed. The details of
the scanning protocol were similar to those described
elsewhere [16]. The diagnosis of NF1 was confirmed
according to the NIH diagnostic criteria [4]. Data were
prospectively collected and retrospectively analyzed. This
study was approved by the institutional review board of
Osaka University Hospital and was conducted according
to institutional ethics guidelines.
Retrospective cohort study of sporadic GISTs
We retrospectively collected NF1-GISTs and sporadic
GISTs from 29 community hospitals and 3 institutions in
Japan between 2001 and 2010. We sent survey forms to 32
hospitals and institutes, which identified 23 primary NF1-
GIST patients among 1314 patients with a primary GIST
who underwent surgery during this period.
Clinical and pathological data for these NF1-GISTs
were collected with tissue samples for pathological
examination when available. Clinicopathologic data for
sporadic GISTs other than those in NF1-GIST patients
were obtained from 19 hospitals. Detailed clinicopatho-
logic data were obtained from 927 of the 1314 primary
sporadic GIST patients. This study was approved by the
institutional review board of Osaka University Hospital
and Osaka Police Hospital and was conducted according
to institutional guidelines. NF1-GISTs were also identi-
fied from a database of reference centers for sarcoma in
France (NetSARC, netsarc.org), which has now gathered
over 21,000 sarcoma tumors since 2010. This database,
updated in real-time by the 26 reference centers in France,
collects data on an estimated 85 % of the sarcoma cases in
this country.
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Pathological diagnosis and mutational analysis
Tissue samples fixed with 10 % buffered formalin and
embedded in paraffin were sectioned (3 lm thick) and used
for hematoxylin and eosin staining (H&E) and immuno-
histochemistry (IHC). IHC was performed using the
ENVISION ? KIT HRP (DAB) system (DAKO, Glostrup,
Denmark) as previously described [17]. Histopathologic
features, including cell shape, mean mitotic number per 50
HPF, and immunophenotype, were analyzed by H&E and
IHC.
When freshly frozen samples were available, total RNA
was extracted using the RNeasy Mini Kit (QIAGEN,
Valencia, CA, USA). All coding regions of the KIT and/or
PDGFRA genes were amplified by polymerase chain
reaction (PCR) after reverse transcription of the extracted
RNA as previously described [17, 18]. When only paraffin
blocks were available, genomic DNA was extracted from
the paraffin sections using the QIAamp DNA Mini Kit
(QIAGEN). Exons 9, 11, 13, and 17 of the KIT gene and
exons 12, 14, and 18 of the PDGFRA gene were amplified
by PCR using previously described primers [17, 19].
Statistical analysis
Statistical analyses were performed using the Chi squared
test, Fisher’s exact test, Student’s t test, and the Mann–
Whitney U test. The recurrence-free survival (RFS) was
calculated from the date of surgery to the date of first tumor
recurrence or to the date of death, censoring living patients
without recurrence at the time of data collection. The
overall survival (OS) was calculated from the date of sur-
gery to the date of death, censoring living patients. RFS
and OS between the groups were compared using the
Kaplan–Meier life-table method with the log-rank test. The
p values were two-sided, and p values \0.05 were con-
sidered significant. The data were analyzed using the Sta-
tistical Package for Social Sciences, version 17.0 (SPSS
Inc., Chicago, IL, USA).
Results
MDCT screening of NF1 patients
Ninety-five NF1 patients, comprising 35 males and 60
females with a median age of 45 years (range 17–80),
received MDCT with or without contrast media. One
patient (a 66-year-old male) exhibited anemia in a pre-
screening blood examination, but all other patients did not
exhibit gastrointestinal symptoms or signs before screen-
ing. Radiographic findings of neoplastic lesions included 6
gastrointestinal tumors (6.3 %; CI: 2.35–13.2 %), which
were later diagnosed as GISTs after pathological exami-
nation of surgical specimens, 6 myoma uteri, 3 adrenal
tumors, 3 intrapelvic masses suspected to be neurofibro-
mas, and 1 mediastinal tumor (Table 1).
All 6 NF1 patients with gastrointestinal tumors under-
went surgery. At the time of surgery, 5 of the 6 NF1
patients had multiple GISTs in the duodenum, jejunum,
and/or ileum, and 1 patient had a single tumor in the
jejunum (Fig. 1a; Table 2). Pathologically, all resected
tumors were KIT-positive, DOG1-positive spindle cell
tumors with few mitotic figures. Furthermore, pathological
examination revealed that all 6 NF1 patients exhibited
hyperplasia of the interstitial cells of Cajal (ICC) in the
normal-appearing adjoining small intestine (Fig. 1b). KIT
and PDGFRA genetic analysis revealed that no resected
tumors exhibited mutations in either gene (Table 2).
NF1-GISTs represent a rare sub-fraction
of sporadic GISTs
Next, we collected histologically confirmed GISTs,
including NF1-GISTs, from patients who underwent sur-
gery between 2001 and 2010 at 32 hospitals in Japan. In
total, 1314 primary GISTs were collected, including 23
primary NF1-GISTs (1.75 %; CI: 1.17–2.61 %). Six of the
23 NF1-GISTs were detected by CT screening, and when
these 6 NF1-patients were excluded from the analysis,
NF1-GISTs accounted for 1.30 % (CI: 0.81–2.07 %) of the
sporadic GISTs. A similar investigation was performed
using data obtained from the French Netsarc/Rreps net-
works study. In this registry, 18 NF1-GIST patients (1.1 %;
CI: 0.75–1.85 %) were identified among 1528 GIST cases.
Thus, NF1-GISTs are estimated at 1.1–1.3 % of primary
sporadic GISTs.
Clinicopathologic features were compared between the
non-NF1-GISTs and NF1-GISTs (Table 3). The NF1-
GISTs more frequently presented as multiple lesions
preferentially located in the small intestine compared with
those of the non-NF1-GISTs. R0 or R1 surgery was less
frequently performed for NF1-GIST patients than for non-
NF1-GIST patients. The mitotic activity of the NF1-GISTs
Table 1 Abdominal lesions indicated by MDCT screening
Lesions N (%)
GIST 6 (6.3 %; CI: 2.35–13.24)
Myoma uteri 6 (6.3 %, 10 % for female)
Adrenal tumor 3 (3.2 %)
Suspected pelvic neurofibroma 3 (3.2 %)
Mediastinal tumor 1 (1.0 %)
Gallstone 4 (4.2 %)
Renal artery aneurysm 1 (1.0 %)
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was significantly lower for mitotic counts (/50 HPF) and
Ki67-positive tumor cells than that of the non-NF1-GISTs.
KIT or PDGFRA mutations were not observed in the
studied NF1-GISTs while 294 of the 303 non-NF1-GISTs
(97.0 %) exhibited KIT or PDGFRA mutations. In patho-
logical examinations, NF1-GIST cells appeared more
spindle-shaped, but this finding was not statistically sig-
nificant. Thus, no significant differences were observed
between the 2 populations with respect to their age, gender,
tumor size, recurrence, cell type, or KIT-immunoreactivity.
With a median follow-up of 3.6 years, 4 NF1-GIST
patients (18.2 %) had relapses in their GISTs, and 225 non-
NF1 (24.9 %) patients had recurrences (Table 3). Peri-
toneal recurrence was the primary relapse site for all 4
NF1-GIST patients. Among the 7 NF1-GIST patients who
underwent R2 surgery, only 2 patients had recurrences
during a median follow-up of 4.3 years. No significant
difference was observed in recurrence risk between the two
groups (p = 0.5946). Two of the 4 recurrent NF1-GIST
patients received imatinib (400 mg/day), and both showed
GIST
40x
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200x
40x
HE
ICC
40x
200x
200x
40x
A
B
Fig. 1 Screening NF-1 patients by MDCT. a Presents a representa-
tive case of an NF-1 patient whose multiple GISTs were detected by
MDCT screening. The patient was a 64-year-old female without signs
or symptoms. The arrows indicate multiple intestinal GISTs.
b Demonstrates ICC hyperplasia (left) in the normal jejunum and a
GIST (right) observed in an NF1 patient with GISTs. The upper
figures show H&E staining, and the lower figures show KIT
immunostaining. ‘‘940’’ and ‘‘9200’’ indicate the magnification of
the objective lens
Table 2 Characteristic features of NF1-GISTs found by the MDCT screening
Age Sex Organs Multiplicity Max size (cm) ICC hyperplasia Cell type Mitosis (/50HPF) Mutations
KIT PDGFRA
66 M D, J Yes 4 Yes Spindle 0 None None
60 M J No 6 Yes Spindle 1 None None
38 F J Yes 3 Yes Spindle 0 None None
51 M D, J Yes 1.8 Yes Spindle 1 None None
31 M J, I Yes 3 Yes Spindle 0 None None
64 F D, J Yes 4.2 Yes Spindle 0 None None
D duodenum, J jejunum, I ileum
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Table 3 Clinicopathologic
features of NF-1 GISTs and
sporadic GISTs
NF-1 GIST Sporadic GIST p valuesa
Japanese set French set Japanese set
No. of NF1-GISTs 22 18 904
Median follow-up (yrs) 3.3 3.6
Median age at dx 61 (26–77) 51 (30–67) 64 (10–93) 0.4302
Gender
Male 9 6 481 0.3543
Female 13 12 423
Median size (cm) 4.1 (1.8–21) 6.6 (1.7–31) 5.0 (0.7–35) 0.5519
Multiplicity
No 6 0 867 \0.0001
Yes 16 0 17
Not available 0 18 20
Location
Esophagus 0 0 9 \0.0001
Stomach 0 1 623
Intestine 22 15 213
Colon 0 0 52
Others 0 2 7
Curabilityb
R0, R1 15 7 784 0.0119d
R2 7 1 104
Not available 0 10 16
Mutationsc
Yes 0 0 294 \0.0001
No 8 6 9
Not available 14 12 601
Recurrence
No 18 8 679 0.6382d
Yes 4 1 225
Not available 0 9 0
Prognosis (OS)
Alive 20 11 734 0.3790d
Dead 2 0 170
Not available 0 7 0
Mitosis (/50HPF) 0.0 (0–8) 1 (0–3) 3.0 (0–300) 0.0093
(n = 22) (n = 3) (n = 902)
Ki67 (%) 0.5 (0.5–15) NA 2.5 (0–50) 0.0022
(n = 21) (n = 248)
Cell type
Spindle 21 4 671 0.0636
Epithelioid or mixed 1 0 75
Not available 0 14 158
NA not available
a Comparison between Japanese NF-1 GISTs and Japanese sporadic GISTs
b Curability of surgery
c Mutations in the KIT and PDGFRA genes
d By the Fisher’s exact test
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disease progression after 3 months of therapy. Thereafter,
both patients received sunitinib (50 mg/day). One patient
showed progressive disease (PD) after 4.5 months, and the
other was diagnosed with PD after 3 months. The mortality
risk was not different between the NF1-GIST patients and
the non-NF1-GIST patients (p = 0.4084): 2 patients
(9.1 %) of the 22 NF1-GIST patients died during follow-
up, while 170 of the non-NF1 patients with sporadic GISTs
(18.8 %) died during follow-up (Table 3; Fig. 2). One of
the NF1-GIST patients died from disease progression, and
the other died following lung cancer. Because the risk of
recurrence is higher in small intestinal GISTs compared
with gastric GISTs [1, 2] and because all NF1-GISTs in
this study were located in the small intestine, we further
examined RFS and OS in NF1-GIST and non-NF1 patients
with small intestinal GISTs (Supplemental Table 1). The
prognosis of the NF1-GIST patients was significantly better
for RFS (p = 0.0383) and marginally better for OS
(p = 0.0776) than for the non-NF1 patients with small
intestinal GISTs (Supplemental Fig. 1). However, the
number of events was limited.
Discussion
Although several retrospective studies have reported an
increased risk for GISTs in NF1 patients, most reports have
suffered from small sample sizes. Furthermore, the fre-
quency of GISTs in NF-1 patients varies greatly in the
literature, ranging from 5 to 29 % [3, 5–8, 10, 11, 14, 20].
One epidemiologic study using the Swedish Cancer Reg-
istry estimated that the lifetime risk of an NF1 patient
developing GISTs could be as high as 7 % [3, 11]. The
clinical incidence of GISTs, and particularly intestinal
GISTs, may vary, as suggested by the number of asymp-
tomatic GISTs identified and studied here. Indeed, NF1-
GIST incidence may have been estimated to be higher in a
report where half of the NF1-GISTs were incidentally
discovered [14], whereas another report estimating a lower
incidence involved predominantly NF1-GIST patients with
gastrointestinal symptoms [8]. Furthermore, all these
reports retrospectively collected NF1-GISTs. In the present
study, we prospectively examined the intra-abdominal
tumors of NF-1 patients by MDCT and observed that 6 of
95 NF1 patients exhibited small-intestinal GISTs. Fur-
thermore, 5 of 6 patients were asymptomatic, suggesting
that a significant number of NF1 patients in middle age
could potentially have subclinical intestinal GISTs. The
prevalence rate is 6.3/100 NF1 patients and is similar to
that obtained by the Swedish Cancer Registry [11]. In our
study, the incidence rate was estimated at 6.3/1000/NF1
patients/year, and the target NF1 patients were typically
between 30 and 60 years old. Thus, GIST incidence in the
NF1 patients was estimated at 200-fold higher than that for
sporadic GISTs, which was postulated at 15 cases per year
per million individuals. Although the usefulness of MDCT
screening for intestinal tumors has not been established,
MDCT can detect intestinal masses larger than 2 cm
[16, 21].
From our study, NF1-GISTs accounted for 1–2 % of all
GISTs, which is consistent with previous reports [8, 14].
Thus, the incidence rate and the proportion of NF1-GISTs
in sporadic GISTs appear very similar in Japanese and
Caucasian populations. Most NF1-GISTs are located in the
small intestine, including the duodenum and proximal
jejunum, and frequently present as multiple tumors with an
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Fig. 2 NF1-GIST patient prognosis. The cumulative recurrence rate
(right panel) and cumulative mortality rate (left panel) are shown.
The median RFS was not reached in the NF1-GIST group, but the
median RFS in the non-NF1-GIST group was estimated at 19.0 years.
Median OS was not reached in both groups
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indolent nature. Contrary to our observations, some studies
indicated that the age of GIST diagnosis tends to be
younger for NF1 patients than for patients with sporadic
GISTs [8, 14]. The mitotic counts for NF1-GISTs were
lower than those for sporadic GISTs in this study; however,
the observed tumor size was similar, contradicting the
results of a previous study without a control arm [8]. Many
reports, including this study, have observed the majority of
NF1-GISTs lack KIT and PDGFRA mutations, [3, 6–10,
12–15, 22] and accordingly, NF1-GISTs might not respond
to imatinib [10].
Neurofibromin is a negative regulator of Ras kinases,
and its loss of function may activate Ras and downstream
kinases, including those in the MEK-MAPK pathway [3].
The MEK-MAPK pathway and the subsequent expression
of ETV1, a master regulator of an ICC-GIST-specific
transcription network and KIT expression [23], is pre-
dominantly activated in NF1-GISTs [15], which may result
in strong KIT-positivity in immunohistochemistry. In this
study, NF1 patients with GISTs exhibited ICC hyperplasia
in the myenteric plexus of the small intestine, as observed
in familial GIST patients with germline KIT mutations
[24]. More than half of NF1-GIST patients exhibited
multiple GISTs in the small intestine [8, 10]. These
observations may be related to the high incidence of GISTs
in NF1 patients. A previous report investigating clonality in
familial GIST patients with germline KIT mutations indi-
cated that cells in the ICC hyperplasia have polyclonal
proliferation, whereas GIST tumor cells show a mono-
clonal development [25].
This study indicated that NF1-GIST patients underwent
more frequent R2 surgery than non-NF1-GIST patients and
that NF1-GIST relapses were mainly peritoneal disease
(Table 3). These results suggest that multiple occurrences of
intestinal GISTs may be responsible for incomplete surgery
and peritoneal recurrence in NF1 patients. However, the
recurrence rate in NF1 patients was similar to that of non-
NF1-GIST patients (Fig. 2). The OS of NF1-GIST patients
was not inferior to that of sporadic GIST patients, although
imatinib failed to show any activity on recurrent NF1-GISTs
[10]. Furthermore, when the prognosis was compared with the
condition of small-intestinal GISTs, the RFS and OS of the
NF1-GIST patients appeared superior to those of the non-
NF1-GIST patients (Supplemental Fig. 1). These results
could be from the indolent nature and low proliferation
activity of the NF1-GISTs [7, 10]. In fact, the mitotic count
and Ki67 staining of the NF1-GISTs were significantly lower
than those of the other sporadic GISTs, and 5 NF1-GIST
patients with R2 surgery had no evidence of recurrence at the
time of analysis, with a median follow-up of 2.5 years.
In summary, we have prospectively evaluated the inci-
dence of GISTs in NF-1 patients. The prevalence rate of
GISTs was estimated at nearly 6 % in adult NF1 patients,
and NF1-GISTs may account for 1–2 % of total sporadic
GISTs. The risk of developing GISTs in NF1 patients is
estimated at nearly 200-fold higher than that in normal
populations. The clinical, pathologic and genetic features
of NF1-GISTs differ from those of sporadic GISTs,
including the development of multiple small intestinal
tumors, an absence of KIT and PDGFRA mutations, and an
indolent nature. Although the NF1-GISTs are frequently
accompanied with multiple tumors and R2 surgery, the
RFS and OS of NF1-GIST patients are similar to those of
the normal population with sporadic GISTs.
Acknowledgments We would like to thank the staff at each hospital
and institution for collecting data for this study. Data collection
collaborators included Drs. Takeshi Omori, Osaka Police Hospital;
Takashi Ishikawa, Niigata University Medical and Dental Hospital;
Masahiro Yamamura, Kawasaki Medical School; Shinya Tokunaga,
Osaka City General Hospital; Syunji Endo, Higashiosaka Municipal
Hospital; Hirofumi Noro, Otemae Hospital; Hiroshi Imamura, Toy-
onaka Municipal Hospital; Atsushi Takeno, Kansai Rosai Hospital;
Kazuo Kinoshita, Sumitomo Hospital; and Masashi Yamamoto, Kobe
University Hospital; and Jean-Francois Emile, Universite´ de Ver-
sailles Saint-Quentin. The work is supported by the Japanese Study
Group on GIST and The Research Group for Rare Neoplasms of
Japan. This work is supported in part by an Grant-in-Aid (H26-
Kakushingann-Ipann-089) from the Ministry of Health, Labor, and
Welfare, Grants-in-Aid (26640110) for Scientific Research from the
Ministry of Education, Culture, Sports, Science and Technology,
Japan, and by the National Cancer Centre Research and Development
Fund (26-A-21). For NetSARC, it is supported in part by Grants from
the French INCa: NETSARC, RREPS, LYRIC-INCA-DGOS-4664,
as well as from the FP7 Eurosarc (FP7-278472).
Compliance with ethical standards
Conflict of interest T. Nishida has received funding for basic
research from Novartis and Bayer. JY Blay received research support
and honoraria from Novartis, Pfizer and Bayer. The others have no
COI.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://crea
tivecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
References
1. Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal
tumours: origin and molecular oncology. Nat Rev Cancer.
2011;11:865–78.
2. Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal
tumour. Lancet. 2013;382:973–8.
3. Brems H, Beert E, de Ravel T, Legius E. Mechanisms in the
pathogenesis of malignant tumours in neurofibromatosis type 1.
Lancet Oncol. 2009;10:508–15.
4. Ferner RE, Huson SM, Thomas N, et al. Guidelines for the
diagnosis and management of individuals with neurofibromatosis
1. J Med Genet. 2007;44:81–8.
J Gastroenterol (2016) 51:571–578 577
123
5. Brasfield RD. Das Gupta TK. von Recklinghausen’s disease: a
clinicopathological study. Ann Surg. 1972;175:86–104.
6. Cheng SP, Huang MJ, Yang TL, et al. Neurofibromatosis with
gastrointestinal stromal tumors: insights into the association. Dig
Dis Sci. 2004;49:1165–9.
7. Takazawa Y, Sakurai S, Sakuma Y, et al. Gastrointestinal stromal
tumors of neurofibromatosis type I (von Recklinghausen’s dis-
ease). Am J Surg Pathol. 2005;29:755–63.
8. Miettinen M, Fetsch JF, Sobin LH, et al. Gastrointestinal stromal
tumors in patients with neurofibromatosis 1: a clinicopathologic
and molecular genetic study of 45 cases. Am J Surg Pathol.
2006;30:90–6.
9. Lee JL, Kim JY, Ryu MH, et al. Response to imatinib in KIT- and
PDGFRA-wild type gastrointestinal stromal associated with
neurofibromatosis type 1. Dig Dis Sci. 2006;51:1043–6.
10. Mussi C, Schildhaus HU, Gronchi A, et al. Therapeutic conse-
quences from molecular biology for gastrointestinal stromal
tumor patients affected by neurofibromatosis type 1. Clin Cancer
Res. 2008;14:4550–5.
11. Zo¨ller ME, Rembeck B, Ode´n A, et al. Malignant and benign
tumors in patients with neurofibromatosis type 1 in a defined
Swedish population. Cancer. 1997;79:2125–31.
12. Kinoshita K, Hirota S, Isozaki K, et al. Absence of c-kit gene
mutations in gastrointestinal stromal tumours from neurofibro-
matosis type 1 patients. J Pathol. 2004;202:80–5.
13. Yantiss RK, Rosenberg AE, Sarran L, et al. Multiple gastroin-
testinal stromal tumors in type I neurofibromatosis: a pathologic
and molecular study. Mod Pathol. 2005;18:475–84.
14. Andersson J, Sihto H, Meis-Kindblom JM, et al. NF1-associated
gastrointestinal stromal tumors have unique clinical, phenotypic,
and genotypic characteristics. Am J Surg Pathol. 2005;29:1170–6.
15. Maertens O, Prenen H, Debiec-Rychter M, et al. Molecular
pathogenesis of multiple gastrointestinal stromal tumors in NF1
patients. Hum Mol Genet. 2006;15:1015–23.
16. Nishida T, Kumano S, Sugiura T, et al. Multidetector CT of high-
risk patients with occult gastrointestinal stromal tumors. Am J
Roentogenol. 2003;180:185–9.
17. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function muta-
tions of c-kit in human gastrointestinal stromal tumors. Science.
1998;279:577–80.
18. Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous
feature of gastrointestinal stromal tumors. Cancer Res.
2001;61:8118–21.
19. Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations
of platelet-derived growth factor receptor alpha gene in gas-
trointestinal stromal tumors. Gastroenterology. 2003;125:660–7.
20. Ghrist TD. Gastrointestinal involvement in neurofibromatosis.
Arch Intern Med. 1963;112:357–62.
21. Jang KM, Min K, Kim MJ, et al. Diagnostic performance of CT
in the detection of intestinal ischemia associated with small-
bowel obstruction using maximal attenuation of region of inter-
est. AJR Am J Roentgenol. 2010;194:957–63.
22. Yamamoto H, Tobo T, Nakamori M, et al. Neurofibromatosis
type 1-related gastrointestinal stromal tumors: a special reference
to loss of heterozygosity at 14q and 22q. J Cancer Res Clin
Oncol. 2009;135:791–8.
23. Chi P, Chen Y, Zhang L, et al. ETV1 is a lineage survival factor
that cooperates with KIT in gastrointestinal stromal tumours.
Nature. 2010;467:849–53.
24. Nishida T, Hirota S, Taniguchi M, et al. Familial gastrointestinal
stromal tumours with germline mutation of the KIT gene. Nat
Genet. 1998;19:323–4.
25. Chen H, Hirota S, Isozaki K, et al. Polyclonal nature of diffuse
proliferation of interstitial cells of Cajal in patients with familial
and multiple gastrointestinal stromal tumours. Gut.
2002;51:793–6.
578 J Gastroenterol (2016) 51:571–578
123
